en · de · es · fr · pt
glossary-desk.peptides9002.com › Info › Mechanism And Evidence Base — Evidence Review

Mechanism And Evidence Base — Evidence Review

By Editorial Desk · published 2026-06-05 · last reviewed 2026-07-28 · Info

batch purity comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.

Mechanism and Evidence Base

Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.

Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.

Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.

Identity and Structural Background

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.

Selank at a glance

PropertyValueNotes
Route studiedIntranasalPredominant route in published reports
Circulation stabilityShort, minutes scalePeptidases cleave it; the tail slows the process
Analytical methodRP-HPLC with mass spectrometryUsed for identity and purity assessment
Reported outcome domainsAnxiety and cognitive measuresDerived from small, mostly regional trials
Regulatory statusMarketed in RussiaAvailability outside that market is limited

Background and Peptide Identity

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Related pages on this site

Stability, Handling, and Analytical Control

Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.

Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.

Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.

Notes from published material

=== Environmental influence === It has been suggested that differences in penis size between individuals are caused not only by genetics, but also by environmental factors such as culture, diet and chemical or pollution exposure. Endocrine disruption resulting from chemical exposure has been linked to genital deformation in both sexes (among many other problems). Chemicals from both synthetic (e.g., pesticides, anti-bacterial triclosan, plasticizers for plastics) and natural (e.g., chemicals found in tea tree oil and lavender oil) sources have been linked to various degrees of endocrine disruption. Both PCBs and the plasticizer DEHP have been associated with smaller penis size. DEHP metabolites measured from the urine of pregnant women have been significantly associated with the decreased penis width, shorter anogenital distance and the incomplete descent of testicles of their newborn sons, replicating effects identified in animals. According to a 2008 study published by the US National Library of Medicine, approximately 25% of US women have phthalate levels similar to those observed in animals. Penile size may decrease as a result of some hormonal therapy combined with external beam radiation therapy. In addition, some estrogen-based fertility drugs like diethylstilbestrol (DES) have been linked to genital abnormalities or a smaller than normal penis (microphallus).

The first reinforcing unit into Kohima, where the Japanese suffered their first major defeat in mainland Asia, was a TA unit, 4th Battalion, Queen's Own Royal West Kent Regiment who went on to hold the Tennis Court in some of the hardest fighting of the battle. Later the commander of the 14th Army, of which they were part, Field Marshal Slim, himself a pre-First World War Territorial became Chief of the Imperial General Staff and a strong promoter of the TA, coining the expression still in use today that Territorials are 'twice a citizen'. One pre-war Guards reservist, (then) Major David Stirling set up the Special Air Service, in North Africa, which fathered several other special forces units, including the Special Boat Service. After VJ Day in August 1945, the Territorial Army was reduced and re-structured.

Sir Frederick Gowland Hopkins (20 June 1861 – 16 May 1947) was an English biochemist who was awarded the Nobel Prize in Physiology or Medicine in 1929, with Christiaan Eijkman, for the discovery of vitamins. He also discovered the amino acid tryptophan, in 1901. He was President of the Royal Society from 1930 to 1935.

=== Evolution and resistance === Due to the high mutation rates of retroviruses, especially due to mutationally sensitive regions (notably the region containing the catalytic triad sequence), and considering that changes to a few amino acids within HIV protease can render it much less visible to an inhibitor, the residues at the active site of this enzyme can change rapidly when under the selective pressure of replication-inhibiting drugs. Despite most of known resistant mutations that can affect the stability of the HIV-1 PR, the protein could still perform its catalytic activity, sometimes facilitated by compensatory mutations. Two types of mutations are generally associated with increasing drug resistance: "major" mutations and "secondary" mutations. Major mutations involve a mutation on the active site of HIV-1 PR, preventing the selective inhibitors from binding it. Secondary mutations refer to molecular changes on the periphery of the enzyme due to prolonged exposure to similar chemicals, potentially affecting inhibitor specificity for HIV-1 PR. One approach to minimizing the development of drug-resistance in HIV is to administer a combination of drugs which inhibit several key aspects of the HIV replication cycle simultaneously, rather than one drug at a time. Other drug therapy targets include reverse transcriptase, virus attachment, membrane fusion, cDNA integration and virion assembly.

Sources: en.wikipedia.org

Further detail

=== Formation from other heterocycles === Imidazole can be synthesized by the photolysis of 1-vinyltetrazole. This reaction will give substantial yields only if the 1-vinyltetrazole is made efficiently from an organotin compound, such as 2-tributylstannyltetrazole. The reaction, shown below, produces imidazole when R1 = R2 = R3 = hydrogen.

Galvani's hypothesis was proven in 1843 by Carlo Matteucci and Emil du Bois-Reymond with their discovery of the action potential. Du Bois-Reymond went on to devise a variety of electrical devices to stimulate and measure electrical activity in nerves and muscles, which he demonstrated to large audiences in Berlin, Paris, and London. In 1856, Guillaume Duchenne photographed electrotherapeutic stimulation of muscle contractions, stating that alternating current was superior to direct current in this stimulation.

== Further reading == Breker, Arno (1970). Patis, Hitler et moi. Paris: Presses de la Cité. Giesler, Hermann (1977). Ein anderer Hitler: Bericht seines Architekten: Erlebnisse, Gespräche, Reflexionen (2nd ed.). Leoni am Starnberger See: Druffel. ISBN 978-3-8061-0820-0. Larsson, Lars Olof (1998). Albert Speer: Plan de Berlin, 1937-1943. [S.I.]: Aam. ISBN 978-2-87143-034-6. O'Donnell, James (1978). The Bunker. New York: Da Capo Press. ISBN 978-0-306-80958-3. Scobie, Alexander (1990). Hitler's State Architecture: The Impact of Classical Antiquity. University Park: Pennsylvania State University Press. ISBN 978-0-271-00691-8. Speer, Albert (1996). Erinnerungen. Frankfurt am Main: Ullstein. ISBN 978-3-550-07616-9. Speer, Albert (1970). Inside The Third Reich. New York: Macmillan. ISBN 978-0-380-00071-5.

Sources: en.wikipedia.org

Background from the literature

== Need for non-dimensionalization and scaling == In addition to reducing the number of parameters, non-dimensionalized equation helps to gain a greater insight into the relative size of various terms present in the equation. Following appropriate selecting of scales for the non-dimensionalization process, this leads to identification of small terms in the equation. Neglecting the smaller terms against the bigger ones allows for the simplification of the situation. For the case of flow without heat transfer, the non-dimensionalized Navier–Stokes equation depends only on the Reynolds Number and hence all physical realizations of the related experiment will have the same value of non-dimensionalized variables for the same Reynolds Number. Scaling helps provide better understanding of the physical situation, with the variation in dimensions of the parameters involved in the equation. This allows for experiments to be conducted on smaller scale prototypes provided that any physical effects which are not included in the non-dimensionalized equation are unimportant.

Campbeltown, a small western coastal town, was once home to over 30 distilleries but now has only three in operation: Glen Scotia, Glengyle, and Springbank. Characteristics vary, but in general, the whiskies are described as "fruity, peaty, sweet, smoky" by the national tourist board; another source published by a marketing company also mentions the "flavor of wet dog, also called wet wool". The Highlands: The Highlands is by far the largest region in Scotland both in area and in whisky production. This massive area has over 30 distilleries on the mainland. Region characteristics: "fruity, sweet, spicy, malty", according to the national tourist board. When the Islands sub-region is included, the total number of distilleries is 47. Some Highland distilleries: Fettercairn, Aberfeldy, Edradour, Balblair, Ben Nevis, Dalmore, Glen Ord, Glenmorangie, Oban, Glendronach, Old Pulteney, Tullibardine and Tomatin. The Islands, an unrecognised sub-region of the Highlands, includes all of the whisky-producing islands other than Islay: Arran, Jura, Mull, Orkney, Raasay and Skye: with their respective distilleries: Arran, Jura, Highland Park, Scapa, Raasay, Talisker and Tobermory. Islay : has nine producing distilleries: Ardbeg, Ardnahoe (the most recent), Bowmore (the oldest, having opened in 1779), Bruichladdich, Bunnahabhain, Caol Ila, Kilchoman, Lagavulin, and Laphroaig. Region Characteristics: distilleries in the south make whisky which is "medium-bodied ... saturated with peat-smoke, brine and iodine" because they use malt that is heavy with peat as well as peaty water.

==== United Kingdom ==== On June 10, 2014, the United Kingdom Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use. The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015.

In 1942, Hugh DeHaven published the classic Mechanical analysis of survival in falls from heights of fifty to one hundred and fifty feet. In 1947, the American Tucker was built with the world's first padded dashboard. It also came with middle headlight that turned with the steering wheel, a front steel bulkhead, and a front safety chamber. In 1949, SAAB incorporated aircraft safety thinking into automobiles making the Saab 92 the first production SAAB car with a safety cage. Also in 1949, the Chrysler Imperial Crown was the first car to come with standard disc brakes.

Sources: en.wikipedia.org

Frequently asked questions

What mechanisms are proposed for Selank?

Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.

How is Selank typically given in studies?

Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.

How strong is the clinical evidence?

Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.

What is the peptide sequence of Selank?

The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.

Network